Intellia Therapeutics, Inc. 8-K

What Happened

• Intellia Therapeutics, Inc. filed an 8‑K on March 2, 2026 announcing an amendment to its Open Market Sale Agreement with Jefferies LLC to increase its at‑the‑market (ATM) offering from $750,000,000 to $1,035,316,650. As of the filing date, Intellia has sold approximately $635,316,650 of common stock under the program. A prospectus supplement (the “New Prospectus”) covering up to $400,000,000 of additional shares will be filed to update the registration materials.
• The company also announced the U.S. Food and Drug Administration has removed the clinical hold on the IND for the MAGNITUDE Phase 3 study of nexiguran ziclumeran (nex‑z) in transthyretin amyloid cardiomyopathy (ATTR‑CM). The original clinical hold was imposed on October 29, 2025 after a patient experienced Grade 4 liver transaminase elevations and increased total bilirubin.

Key Details

• ATM increase: from $750,000,000 to $1,035,316,650 (Amendment effective March 2, 2026).
• Shares sold to date under program: ~$635,316,650; New Prospectus covers up to $400,000,000 of Additional Shares (including ~$114,683,350 not yet sold under the Existing Prospectus).
• Sales agent and fees: Jefferies LLC acts as sales agent on a best‑efforts basis; compensation up to 3.0% of gross proceeds.
• Clinical‑trial update: FDA lifted the MAGNITUDE IND hold; Intellia and FDA agreed on mitigation measures (enhanced liver monitoring, short‑term steroid guidance for certain elevations, exclusion of patients with specified liver abnormalities; additional exclusions for MAGNITUDE include recent cardiovascular instability and ejection fraction <25%).

Why It Matters

• Capital flexibility and dilution risk: The larger ATM gives Intellia the ability to raise up to ~$1.035B of equity over time, providing funding flexibility but also creating potential dilution for existing shareholders if shares are sold. Jefferies’ fees (up to 3%) and indemnities are part of the amended agreement.
• Clinical development progress: The FDA’s removal of the clinical hold for MAGNITUDE allows Intellia to pursue resumption of enrollment for the Phase 3 ATTR‑CM trial, subject to the agreed mitigation measures and ongoing engagement with investigators and regulators. The company reported the prior safety event that prompted the hold, and the filing describes specific safety monitoring and exclusion criteria now added to the trials.
• Near‑term investor focus: Watch for the filed prospectus supplement (New Prospectus) and any placement notices (which would signal actual share sales), and for operational updates on trial enrollment timelines and implementation of the mitigation measures described in the filing.